AllSci News
Albert Einstein to optimize RNA vaccine designs for pandemics with NIAID support
Albert Einstein College of Medicine has received a USD 2.09 million NIAID award to advance RNA vaccine design against emerging viral pathogens with pandemic...
University of Arizona gets NIAID backing for CD4+ T cell profiling platform
The University of Arizona has received a USD 3.19 million R01 grant from the National Institute of Allergy and Infectious Diseases to develop a novel assay...
Actimed regains full control of S-oxprenolol after five-year partnership with Faraday
UK-based Actimed Therapeutics has reacquired full global rights to S-oxprenolol (ACM-002), an anabolic-catabolic transforming agent (ACTA) small molecule,...
TransThera wins first China approval in post-FGFR cholangiocarcinoma
China's National Medical Products Administration (NMPA) has granted conditional marketing approval to Yochanra (tinengotinib) tablets for adult patients...
Ensysce expands into neuroplastogenic pain with USD 77m Cy Biopharma acquisition
San Diego-based Ensysce Biosciences (Nasdaq: ENSC) has completed the acquisition of Cy Biopharma, a privately held clinical-stage company developing...
Tarsus builds retina franchise in USD 800 million Alkeus deal
Tarsus Pharmaceuticals (Nasdaq: TARS) has agreed to acquire Alkeus Pharmaceuticals, a privately held retinal disease biotech, for approximately USD 450...
Mediar partners with Ono Pharma on fibro-inflammatory discovery
Boston-based Mediar Therapeutics has entered a collaboration and option agreement with Japan-based Ono Pharmaceutical to develop antibody therapies for...
Bezisterim meets motor and non-motor endpoints in phase II early Parkinson's trial.
BioVie (Nasdaq: BIVI) reported that bezisterim, its investigational oral anti-inflammatory compound, met prespecified endpoints in a Phase II trial in early...
Sophia Genetics expands AstraZeneca partnership with two cDX programs
Switzerland-based Sophia Genetics (Nasdaq: SOPH) has entered a multi-year global collaboration with AstraZeneca (NYSE: AZN) to develop, validate, and deploy...
Luye clears US bridging milestone for first dual-mechanism TD therapy
Luye Pharma Group (HKEX: 02186) announced on August 5 the successful completion of a US pharmacokinetic (PK) bridging study of LY03015, its investigational...
Hengrui, Braveheart's cardiac myosin inhibitor shows strong early efficacy against cardiomyopathy
Hengrui Pharma and Braveheart Bio reported Phase 2 results for HRS-1893 (BHB-1893), a selective small-molecule cardiac myosin inhibitor, in patients with...
BMS deploys Schrödinger's agentic AI platform across drug discovery
Schrödinger (Nasdaq: SDGR) and Bristol Myers Squibb announced a strategic software agreement to deploy Bunsen, Schrödinger's agentic AI co-scientist...
Braveheart Bio ups IPO pricing for USD 382.5m take-home
Braveheart Bio, Inc. (Nasdaq: BRVE), a San Francisco-based clinical-stage biopharmaceutical company developing a next-generation oral cardiac myosin...
Eli Lilly Q2'26: Retatrutide heads toward filing amid BLA dispute
Eli Lilly Q2 2026 earnings call, held on August 5, 2026, was dominated by the completion of the retatrutide Phase III registrational package and a contested...
Novo Nordisk Q2'26: ZEUS failure overshadows obesity pipeline advances
Novo Nordisk A/S (NOVO) held its Q2 2026 earnings call on August 5, 2026, during which the Phase III failure of ziltivekimab in cardiovascular outcomes...
The AllSci Brief
Systematic R&D and deal news. Daily.